FINWIRES · TerminalLIVE
FINWIRES

SHA:603858

8 stories mentioning SHA:603858Updated just now

Every FINWIRES story that references SHA:603858, newest first.

Asia

Shareholders at Shandong Buchang Pharmaceuticals Subsidiary to Divest Stakes

Three shareholders of Shandong Buchang Pharmaceuticals (SHA:603858) subsidiary Shandong Buchang Zhongxinkang Pharmaceutical Technology will sell their stakes to two individuals, according to a Tuesday filing with the Shenzhen bourse.Chen Xuebo will divest his 2% stake in Zhongxinkang to Zhang Jiancan for 60,748 yuan, while Mao Xiaoteng and Gao Jinliang will sell each of their 1% stakes to Su Gui for 30,374 yuan each.Zhang is a sales director at Shandong Buchang Zhenze Pharmaceutical Technology, while Su Gui is a director of third terminal sales at Zhongxinkang.

SHA:603858
Asia

Buchang Pharma's Subsidiary Gets Renewed License

Shandong Buchang Pharmaceuticals' (SHA:603858) subsidiary, Shanghai Hepu Medical Devices, obtained a renewed medical device business license after updating its addresses, according to a Shanghai bourse filing on Thursday.Shanghai's Xuhui District Market Supervision Administration handed over the renewed license to the company.The registered address was changed to Rooms 201A, 201B, Building 8 & 12, Lane 1420 Zhongshan West Road, Xuhui District, Shanghai from Room C09, C10, 3rd Floor, Nos. 4936, 4938, 4940 XinFeng Road, Haiwan Tourism Area, Fengxian District, Shanghai.The warehouse addresses in Fengxian District and Huangpu District were also specified in the renewed license.Moreover, the company's business scope was updated, adding more devices under its Class III classification, such as sterile devices, implant materials and contact lenses.The Chinese pharmaceutical company's shares fell 2% during the afternoon trade.

SHA:603858
Asia

Buchang Pharma's Subsidiary to Set Up Joint Venture

Shandong Buchang Pharmaceuticals' (SHA:603858) subsidiary, Shanghai Hepu Medical Technology, agreed to established a joint venture with Sichuan Lindong Enterprise Management Center (Limited Partnership), according to Shanghai bourse filing on Wednesday.The joint venture company, Sichuan Hepu Tongchuang Medical Technology, will have a registered capital of 4.5 million yuanHepu Medical Tech will own 70% of the venture after investing 3.2 million yuan, while Sichuan Lindong will own the remaining 30% after investing 1.4 million yuan.

SHA:603858
Asia

Shandong Buchang Pharmaceuticals Gets Chinese Provincial Approval for Calcium Carbonate Production Line

Regulators in Hebei, China approved changes to Shandong Buchang Pharmaceuticals' (SHA:603858) workshop production license for its calcium carbonate tablet production line, according to a Tuesday bourse filing.

SHA:603858
Asia

Buchang Pharma Unit Completes Business Scope Expansion

Shandong Buchang Pharmaceuticals (SHA:603858) subsidiary Buchang Qihang Pharmaceutical Sales completed the industrial and commercial registration changes to expand its business scope, according to a Wednesday filing with the Shanghai bourse.The subsidiary, with a registered capital of 6 million yuan, now holds approval for pharmaceutical retail and wholesale, Class III medical device operations, disinfection device sales, and road freight transport.Shares of the pharmaceutical company were down 1% Wednesday.

SHA:603858
Asia

Buchang Pharma Subsidiary Adds Health Food to Business Scope

Shandong Buchang Pharmaceuticals (SHA:603858) subsidiary Shandong Buchang Qihang Pharmaceutical Sales added pre-packaged health food sales to its business scope.The change was made due to operational and management needs, according to a Tuesday filing with the Shanghai bourse.

SHA:603858
Asia

Buchang Pharma Plans Share Buyback of Up to 150 Million Yuan

Shandong Buchang Pharmaceuticals (SHA:603858) plans to repurchase shares worth between 75 million yuan and 150 million yuan, according to a Shanghai bourse filing on Tuesday.The share buyback will be implemented within 12 months after the approval of the board of directors.Each share will be priced up to 21 yuan.The repurchased shares will be used for the company's employee stock ownership plan, equity incentives, and convertible bond conversion.

SHA:603858
Asia

Buchang Pharma Unit to Invest 3.2 Million Yuan in Chengdu Medtech JV

Shandong Buchang Pharmaceuticals (SHA:603858) controlled unit Shanghai He pu Medical Technology will invest 3.2 million yuan for a 70% stake in a new medical technology company in Chengdu, China.Sichuan He pu Tongchuang Medical Technology will have a registered capital of 4.5 million yuan, according to a Friday filing with the Shanghai bourse.The joint venture will engage in medical device sales, technical services and equipment repair.Shares of the pharmaceutical company were down 2% in recent trade.

SHA:603858

Track with the FINWIRES app suite

FolioX
FolioX
Track SHA:603858 in your portfolio
WheelAI
WheelAI
Analyze SHA:603858 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHA:603858